ASCO 2013 - Poster: Long-term safety and efficacy analysis of abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer without prior chemotherapy (COU-AA-302)

CHICAGO, IL USA (UroToday.com) - Presented by Dana Rathkopf,1 Matthew R. Smith,2 Johann S. de Bono,3 Christopher J. Logothetis,4 Neal D. Shore,5 Paul de Souza,6 Karim Fizazi,7 Peter F.A. Mulders,8 Paul Mainwaring,9 John D. Hainsworth,10 Tomasz M. Beer,111 Scott North,12 Yves Fradet,13 Thomas Griffin,1 Youn C. Park,15 Thian Kheoh,14 Eric J. Small,16 Howard I. Scher,1 Arturo Molina,14 and Charles J. Ryan16 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

 

ASCO-2013-Rathkopf-Poster-thumb

 

Click HERE to listen to a podcast by Charles J. Ryan, MD, one of the authors of this study 

1Memorial Sloan-Kettering Cancer Center, New York, NY; 2Massachusetts General Hospital Cancer Center, Boston, MA; 3Institute of Cancer Research and Royal Marsden Hospital, Sutton, UK; 4MD Anderson Cancer Center, Houston, TX; 5Carolina Urologic Research Center, Myrtle Beach, SC; 6University of Western Sydney School of Medicine, Ingham Institute, Liverpool, Australia; 7Institut Gustave Roussy, University of Paris Sud, Villejuif, France; 8Radboud University Medical Centre, Nijmegen, The Netherlands; 9Haematology and Oncology Clinics of Australia, Brisbane, Australia; 10Sarah Cannon Research Institute, Nashville, TN; 11Oregon Health & Science University Knight Cancer Institute, Portland, OR; 12Cross Cancer Institute, Edmonton, Alberta, Canada; 13Laval University, Quebec, Canada; 14Janssen Research & Development, Los Angeles, CA; 15Janssen Research & Development, Raritan, NJ; 16Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 

 

The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer." 

asco x

View Full ASCO 2013 Coverage